Vivo Capital, LLC

13F Portfolio Filings

Most recent 13F
Q4 2023
Location
Palo Alto, CA
CIK
0001674712
All SEC filings
View on sec.gov
Holdings Value
Quarter Holdings Value ($000) Top Holdings Form Type Date Filed Filing ID
Q4 2023 47 1,221,329 SLNO, GRCL, I9SA.HA, HRMY 13F-HR 2/6/2024 000121390024010646
Q3 2023 53 912,764 GTH, SLNO, HRMY, I9SA.HA 13F-HR 11/8/2023 000121390023084732
Q2 2023 48 1,448,793 SINX, HRMY, I9SA.HA, AVDL 13F-HR 8/14/2023 000121390023067000
Q1 2023 48 1,441,130 SINX, GTH, I9SA.HA, HRMY 13F-HR 5/15/2023 000121390023039212
Q4 2022 48 868,545 HRMY, TERN, VRDN, ALXO 13F-HR 2/13/2023 000121390023010818
Q3 2022 51 905,807 HRMY, TIL, VTYX, I9SA.HA 13F-HR 11/14/2022 000121390022072092
Q2 2022 49 995,881 HRMY, SRRA, TIL, ISEE 13F-HR 8/15/2022 000121390022047557
Q1 2022 54 1,452,156 HRMY, New Frontier Health Corp, TIL, ISEE 13F-HR 5/13/2022 000121390022026422
Q4 2021 55 1,658,443 TIL, HRMY, New Frontier Health Corp, ISEE 13F-HR 2/11/2022 000121390022006960
Q3 2021 60 2,227,158 ALXO, TIL, HRMY, New Frontier Health Corp 13F-HR 11/15/2021 000121390021059130
Q2 2021 59 2,310,071 TIL, ALXO, ASND, AMRS 13F-HR 8/16/2021 000121390021042960
Q1 2021 63 2,845,273 TIL, ALXO, AMRS, ASND 13F-HR 5/17/2021 000121390021026949
Q4 2020 59 2,240,895 ALXO, ASND, HRMY, TARS 13F-HR 2/16/2021 000121390021009490
Q3 2020 64 1,730,387 ASND, ALXO, HRMY, NEW FRONTIER HEALTH CORP 13F-HR 11/13/2020 000121390020036943
Q2 2020 54 1,394,707 ASND, LEGN, New Frontier Health Corp, GTH RESTATEMENT 11/13/2020 000121390020036945
Q1 2020 53 1,103,888 ASND, New Frontier Health Corp, KDMN, ARQT 13F-HR 5/15/2020 000121390020012587
Q4 2019 49 1,372,681 Ascendis Pharma A/S, New Frontier Health Corp, Aurinia Pharmaceuticals Inc., Crinetics Pharmaceuticals Inc RESTATEMENT 2/25/2020 000121390020004679
Q3 2019 49 878,828 Ascendis Pharma A/S, Arrowhead Pharmaceuticals Inc, Crinetics Pharmaceuticals Inc, Tricida, Inc. 13F-HR 11/13/2019 000121390019023217
Q2 2019 46 1,067,129 ASND, CRNX, ARWR, TCDA 13F-HR 8/13/2019 000121390019015546
Q1 2019 49 1,002,882 ASND, CRNX, CDXS, ARWR 13F-HR 5/14/2019 000161577419007680
Q4 2018 45 783,077 ASND, CRNX, Biohaven Pharmaceutical Holding Company Ltd, CDXS 13F-HR 2/13/2019 000161577419002398
Q3 2018 44 992,161 ASND, CRNX, Biohaven Pharmaceutical Holding Company Ltd, CDXS 13F-HR 11/13/2018 000161577418012532
Q2 2018 40 776,070 ASND, Biohaven Pharmaceutical Holding Company Ltd, KDMN, CDXS 13F-HR 8/10/2018 000161577418007846
Q1 2018 34 705,919 VYNE, ASND, Biohaven Pharmaceutical Holding Company Ltd, CDXS 13F-HR 5/15/2018 000121465918003735
Q4 2017 30 466,864 ASND, Biohaven Pharmaceutical Holding Company Ltd, ACRS, APLS 13F-HR 2/9/2018 000121465918001028
Q3 2017 29 494,813 Biohaven Pharmaceutical Holding Company Ltd, ACRS, ASND, NBRV 13F-HR 11/13/2017 000121465917006608
Q2 2017 26 397,070 ACRS, Biohaven Pharmaceutical Holding Company Ltd, ASND, NBRV 13F-HR 8/2/2017 000121465917004735
Q1 2017 23 339,946 ACRS, ASND, NBRV, CDXS 13F-HR 5/15/2017 000121465917003338
Q4 2016 25 303,451 ACRS, ASND, CDXS, NBRV RESTATEMENT 4/6/2017 000121465917002413
Q3 2016 22 320,887 ACRS, ASND, EIGR, CDXS 13F-HR 11/14/2016 000121465916014565
Q2 2016 23 366,183 SGNT, ACRS, EIGR, NBRV 13F-HR 8/15/2016 000121465916013202
Q1 2016 24 398,682 ACRS, SGNT, Biotie Therapies Corp., NBRV 13F-HR 5/16/2016 000121465916011605
Additional filings from Vivo Capital, LLC that have since been restated